This site is intended for Healthcare professionals only.

Lupin gets EIR from USFDA for Nagpur facility


Lupin gets EIR from USFDA for Nagpur facility

New Delhi: Drug firm Lupin said it has received an establishment inspection report (EIR) from the US health regulator after the successful inspection of its Nagpur facility.

The plant was inspected by the United States Food and Drug Administration (USFDA) in May 2018, Lupin said in a filing to BSE.

Commenting on the development, Lupin MD Nilesh Gupta said, “The successful completion of the Nagpur facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards.”

Earlier in May, in a regulatory filing, Lupin had said that the US health regulator had completed the inspection of the Nagpur facility without making any observations.



Source: PTI
0 comment(s) on Lupin gets EIR from USFDA for Nagpur facility

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted